137 related articles for article (PubMed ID: 35533038)
21. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
[TBL] [Abstract][Full Text] [Related]
22. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
[TBL] [Abstract][Full Text] [Related]
23. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma.
Wehner MR; Linos E; Parvataneni R; Stuart SE; Boscardin WJ; Chren MM
JAMA Dermatol; 2015 Apr; 151(4):382-8. PubMed ID: 25588079
[TBL] [Abstract][Full Text] [Related]
24. β-HPV Infection Correlates with Early Stages of Carcinogenesis in Skin Tumors and Patient-Derived Xenografts from a Kidney Transplant Recipient Cohort.
Borgogna C; Olivero C; Lanfredini S; Calati F; De Andrea M; Zavattaro E; Savoia P; Trisolini E; Boldorini R; Patel GK; Gariglio M
Front Microbiol; 2018; 9():117. PubMed ID: 29459852
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of human papillomavirus DNA in cutaneous neoplasms from renal allograft recipients supports a possible viral role in tumour promotion.
Stark LA; Arends MJ; McLaren KM; Benton EC; Shahidullah H; Hunter JA; Bird CC
Br J Cancer; 1994 Feb; 69(2):222-9. PubMed ID: 8297718
[TBL] [Abstract][Full Text] [Related]
26. Is the presence of Merkel cell polyomavirus and human papillomavirus DNA in keratinocyte cancers and precancers associated with HIV status? A case-control study.
Goolamali SI; Shim TN; Purdie K; Mladkova N; Francis N; Harwood CA; Bunker CB
Clin Exp Dermatol; 2024 Feb; 49(3):263-266. PubMed ID: 37793080
[TBL] [Abstract][Full Text] [Related]
27. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.
Chatterjee A
Expert Rev Vaccines; 2014 Nov; 13(11):1279-90. PubMed ID: 25256262
[TBL] [Abstract][Full Text] [Related]
28. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Connolly K; Manders P; Earls P; Epstein RJ
Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018
[TBL] [Abstract][Full Text] [Related]
29. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus infection and skin cancer risk in organ transplant recipients.
Bouwes Bavinck JN; Feltkamp M; Struijk L; ter Schegget J
J Investig Dermatol Symp Proc; 2001 Dec; 6(3):207-11. PubMed ID: 11924829
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Systematic Review.
Schauder DM; Kim J; Nijhawan RI
JAMA Dermatol; 2020 Oct; 156(10):1117-1124. PubMed ID: 32639538
[TBL] [Abstract][Full Text] [Related]
32. Detection of human papillomavirus DNA in squamous cell carcinomas of a patient with mycosis fungoides: report of a case.
Liranzo MO; Golitz L; Shroyer KR
J Cutan Pathol; 1997 Jan; 24(1):47-50. PubMed ID: 9027633
[TBL] [Abstract][Full Text] [Related]
33. Chapter 16: HPV vaccines in immunocompromised women and men.
Palefsky JM; Gillison ML; Strickler HD
Vaccine; 2006 Aug; 24 Suppl 3():S3/140-6. PubMed ID: 16950001
[TBL] [Abstract][Full Text] [Related]
34. Langerhans cells in benign, premalignant and malignant skin lesions of renal transplant recipients and the effect of retinoid therapy.
Gibson GE; O'Grady A; Kay EW; Leader M; Murphy GM
J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):130-6. PubMed ID: 9553909
[TBL] [Abstract][Full Text] [Related]
35. [Human papillomavirus-associated warts in organ transplant recipients. Incidence, risk factors, management].
Krüger-Corcoran D; Stockfleth E; Jürgensen JS; Maltusch A; Nindl I; Sterry W; Lange-Asschenfeldt B; Ulrich C
Hautarzt; 2010 Mar; 61(3):220-9. PubMed ID: 20165825
[TBL] [Abstract][Full Text] [Related]
36. Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis.
Wang J; Aldabagh B; Yu J; Arron ST
J Am Acad Dermatol; 2014 Apr; 70(4):621-629. PubMed ID: 24629358
[TBL] [Abstract][Full Text] [Related]
37. Development of a β-HPV vaccine: Updates on an emerging frontier of skin cancer prevention.
Gupta R; Rady PL; Doan HQ; Tyring SK
J Clin Virol; 2020 May; 126():104348. PubMed ID: 32334327
[TBL] [Abstract][Full Text] [Related]
38. Absence of human papillomavirus in squamous cell carcinomas of nongenital skin from immunocompromised renal transplant patients.
Smith SE; Davis IC; Leshin B; Fleischer AB; White WL; Feldman SR
Arch Dermatol; 1993 Dec; 129(12):1585-8. PubMed ID: 8250579
[TBL] [Abstract][Full Text] [Related]
39. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
40. A qualitative study investigating knowledge and attitudes regarding human papillomavirus (HPV) and the HPV vaccine among parents of immunosuppressed children.
Seale H; Trung L; Mackie FE; Kennedy SE; Boros C; Marshall H; Tidswell J; Shaw PJ; Montgomery K; MacIntyre CR
Vaccine; 2012 Nov; 30(49):7027-31. PubMed ID: 23059356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
